4AB Stock Overview
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 1/6 |
Financial Health | 3/6 |
Dividends | 4/6 |
Rewards
Risk Analysis
+ 1 more risk
AbbVie Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$165.00 |
52 Week High | US$167.30 |
52 Week Low | US$119.00 |
Beta | 0.56 |
1 Month Change | -0.24% |
3 Month Change | 19.74% |
1 Year Change | 12.29% |
3 Year Change | 82.32% |
5 Year Change | 130.22% |
Change since IPO | 553.21% |
Recent News & Updates
Recent updates
Shareholder Returns
4AB | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0.3% | 3.3% | 1.6% |
1Y | 12.3% | 35.8% | 6.4% |
Return vs Industry: 4AB underperformed the German Biotechs industry which returned 35.3% over the past year.
Return vs Market: 4AB exceeded the German Market which returned 6.4% over the past year.
Price Volatility
4AB volatility | |
---|---|
4AB Average Weekly Movement | 2.8% |
Biotechs Industry Average Movement | 5.9% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4AB has not had significant price volatility in the past 3 months.
Volatility Over Time: 4AB's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 50,000 | Rick Gonzalez | https://www.abbvie.com |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine.
AbbVie Inc. Fundamentals Summary
4AB fundamental statistics | |
---|---|
Market cap | €291.52b |
Earnings (TTM) | €4.45b |
Revenue (TTM) | €50.11b |
65.6x
P/E Ratio5.8x
P/S RatioIs 4AB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4AB income statement (TTM) | |
---|---|
Revenue | US$54.32b |
Cost of Revenue | US$16.73b |
Gross Profit | US$37.59b |
Other Expenses | US$32.77b |
Earnings | US$4.82b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 2.72 |
Gross Margin | 69.21% |
Net Profit Margin | 8.87% |
Debt/Equity Ratio | 573.6% |
How did 4AB perform over the long term?
See historical performance and comparisonDividends
3.5%
Current Dividend Yield220%
Payout RatioDoes 4AB pay a reliable dividends?
See 4AB dividend history and benchmarksAbbVie dividend dates | |
---|---|
Ex Dividend Date | Apr 12 2024 |
Dividend Pay Date | May 15 2024 |
Days until Ex dividend | 17 days |
Days until Dividend pay date | 50 days |
Does 4AB pay a reliable dividends?
See 4AB dividend history and benchmarks